<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080726</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ESOM-301</org_study_id>
    <nct_id>NCT04080726</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of HIP1601 Capsule</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Compare Efficacy and Safety of HIP1601 40mg and HGP1705 40mg in Patients With Erosive Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in
      patients with erosive gastroesphageal reflux disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicenter, randomized, double-blind, parallel group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Complete healing rate</measure>
    <time_frame>at 4 weeks or 8 weeks</time_frame>
    <description>percentage of subjects whose erosion is completely cured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete healing rate</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>percentage of subjects whose erosion is completely cured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resolution rate of each symptom in GERD</measure>
    <time_frame>at 4,8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of heartburn-free days, acid regurgitation-free days</measure>
    <time_frame>at 1, 2, 4, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of heartburn-free nights, acid regurgitation-free nights</measure>
    <time_frame>at 1, 2, 4, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained resolution heartburn, acid regurgitation</measure>
    <time_frame>at 4 weeks or 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained resolution of nocturnal heartburn, nocturnal acid regurgitation</measure>
    <time_frame>at 4 weeks or 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of use of relief drugs and average usage per day</measure>
    <time_frame>at 4 weeks or 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Erosive Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>HIP1601+HGP1705 Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIP1601+HGP1705 Placebo for 4weeks. if not fully cured, take HIP1601+HGP1705 Placebo for addtional 4weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HGP1705+HIP1601 Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGP1705+HIP1601 Placebo for 4weeks. if not fully cured, take HGP1705+HIP1601 Placebo for addtional 4weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIP1601</intervention_name>
    <description>Oral esomeprazole</description>
    <arm_group_label>HIP1601+HGP1705 Placebo</arm_group_label>
    <other_name>esomeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1705</intervention_name>
    <description>Oral Nexium Tab</description>
    <arm_group_label>HGP1705+HIP1601 Placebo</arm_group_label>
    <other_name>Nexium Tab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIP1601 Placebo</intervention_name>
    <description>Oral Placebo</description>
    <arm_group_label>HGP1705+HIP1601 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1705 Placebo</intervention_name>
    <description>Oral Placebo</description>
    <arm_group_label>HIP1601+HGP1705 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19≤ age ≤ 75

          -  Esophago-Gastro-Duodenoscopy LA classification ≥ grade A

          -  Patients experienced heartburn or acid regurgitation within 7 days of screening day

          -  Patients understood the consents and purpose of this trial and signed consent form

        Exclusion Criteria:

          -  Has malignancy in the upper gastrointestinal tract, digestive ulcer, bleeding disorder
             or signs of gastrointestinal bleeding

          -  Has a severe liver disorder(at screening day, AST or ALT level exceeds 3 times more
             than normal upper range)

          -  Has a clinically significant renal failure(at screening day, MDRD eGFP ≤ 59
             mL/min/1.73m2 or Serum creatinine &gt;2.0mg/dL)

          -  Uncontrolled diabetes mellitus

          -  Before screening EGD, a patient who has taken H2-receptor antagonist or PPI within 2
             weeks

          -  Before screening EGD, a patient who has taken drugs containing following list within 1
             weeks : warfarin, anticholinergics for spasmolytic GI, antineoplastic agents,
             salicylates(except 100mg a day for prevention of cardiovascular disease), steroids,
             propulsives, sucralfate, NSAIDs, other antacids(e.g. antacids of prostaglandin
             analogs, antacids of aluminum/magnesium)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hunyong Jung, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-A Jung, Ph.D</last_name>
    <phone>02-410-9038</phone>
    <phone_ext>9038</phone_ext>
    <email>jajung@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hunyong Jung, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hun Young Jung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

